Thrombolex, Inc.   Report issue

For profit Phase 1
Founded: Doylestown PA United States (2016)
Status: No NME R&D (2016)

Organization Overview

First Clinical Trial
2019
NCT03927508
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Thrombolex, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

alteplase (Activase) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Embolism (Phase 1)

Pulmonary Embolism (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1